BioNTech CEO says possible to adapt vaccine quickly for Omicron

Reading Time: 2 minutes FRANKFURT, Dec 3 (Reuters) – Germany’s BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, its CEO Ugur Sahin said, adding that despite the mutation shots should continue to protect people against severe disease. BioNTech and Pfizer Inc together produced one of the